de
Profile
Strategy
Organisation
Investment Guidelines
Corporate Governance
Articles of Association
Sitemap
Company
Profile
Strategy
Organisation
Board of Directors
Management
Cayman Subsidiary
Investment Manager
Investment Advisor Europe
Investment Advisor USA
Investment Guidelines
Corporate Governance
Articles of Association
Portfolio
Monthly Overview
Quarterly Overview
Largest Investments
Private Companies
Specialised Venture Capital Funds
Public Companies
Investors
Performance
Share Price
Net Asset Value (NAV)
Price Convertible Bond
Key Figures
Financial Reports
Share Buyback Programme
Press Releases
Securities
Management Transactions
Disclosure of Shareholdings
Company Presentation
Calendar
FAQ
News Registration
Contact
Downloads
Financial Reports
Financial Reports 2009/2010
Financial Reports 2008/2009
Archive
Press Releases
2010
2009
Archive
Capital Market Transactions
Company Presentation
Corporate Documents
Contact
HBM BioVentures Ltd
Cayman Subsidiary
Investment Manager
Investment Advisor Europe
Investment Advisor USA
Contact Form
News
Press Releases
»
Disclosure of shareholdings according to articles 9 and 21 of the Stock Exchange Ordinance of the Swiss Financial Market Supervisory Authority FINMA
»
ChemoCentryx receives an option payment of USD 35 million from GlaxoSmithKline for a licensing agreement
»
Major financing round for PTC Therapeutics at 2.2 times the previous valuation
»
Archive
Financial Reports
»
Quarterly Report December 2009
»
Archive
Share Price
SIX Swiss Exchange Ticker
HBMN
Key Figures
as at 28.02.2010
CHF
NAV
per share
68.38
Net assets
693 Mio.
Search
News Registration
Sign up now
